E-Learning

(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergHo Chi Minh City Opens First Metro Line After Years of DelayReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh

The benchmark US stock measures were mostly trending lower before the opening bell Monday, as trader

Broadcom shares have added around $250 billion in value this month.

Volkswagen shares were down 3% in early trade on Monday with analysts citing uncertainty about the automaker's cost-cutting deal with unions and likely headwinds in 2025. It fell short of management's initial ambitions and market expectations, and lacked a sense of urgency, according to Jefferies analyst Philippe Houchois. VW's earnings momentum is also unlikely to improve significantly next year given weak demand in China and potential tariffs after Donald Trump's election, they added.

Wall Street's 'Santa Claus Rally' has typically boosted stocks by around 1.3% over the final five trading days of the year, as well as the first two of the next.

Compare the best money market account rates available today and find out which banks have the best offers.

These three stocks were expected to soar by double digits this year. Instead, they dropped by the same amount. What went wrong?

Investors in Intel's stock haven't had much to celebrate in 2024, with the shares losing more than half their value. Next year could be challenging too.

Wealthy investors are flocking to artificial intelligence startups — and fueling a private market renaissance.

Stocks have struggled ahead of the holidays despite Friday’s rally.